Genmab A/S
http://www.genmab.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genmab A/S
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Poland’s Quiet Pivot From Generics To Innovative Treatments
Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.
Physician Familiarity May Determine Epkinly Uptake In Follicular Lymphoma
AbbVie/Genmab’s anti-CD20 bispecific is the first subcutaneous drug in the class to win approval for FL, but despite that advantage, doctors may pick the drug they know best.
The Scrip Awards Podcast, Episode 1: Genmab: The Ongoing Evolution Of Europe’s Antibody Powerhouse
A new podcast series marking 20 years of the Scrip Awards and their recognition of biopharma sector innovation.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice